Lower Dose Of Imatinib Provides Outcomes Similar To The Standard Dose Imatinib In Japanese Patients With Early Chronic-Phase Cml: The Interim Analyses Of Jalsg Cml202 Study
BLOOD(2007)
Abstract
Background: The dose of imatinib 400 mg is considered to be standard for chronic-phase chronic myeloid leukemia (CML) based on the IRIS study. However, the optimal dose of imatinib is not yet settled and the response of lower dose imatinib has not been investigated. Lower dose of imatinib might be enough in Asian patients since the results of PK in IRIS study showed weak correlation between imatinib trough level and body weight. We showed the results of the interim analysis of JALSG CML202 study and analyzed the efficacy of imatinib according to the mean daily dose level.
MoreTranslated text
Key words
standard dose imatinib,jalsg cml202 study,japanese patients,chronic-phase
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined